Latest Leadership News

Beonic Limited reported a 6.5% increase in annual recurring revenue to $17.8 million and a significant gross margin improvement to 75.5%, driven by new global contracts and disciplined cost management. The company targets cash flow breakeven in Q4 FY25 and an EBITDA margin of up to 15%.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Trigg Minerals has solidified its ownership of the Wild Cattle Creek antimony deposit with NSW government approval and confirmed high-grade antimony and tungsten mineralisation beneath the site. The company also expanded its New South Wales footprint through strategic acquisitions of historic gold and antimony projects.

INOVIQ Limited reports significant progress in its exosome-based cancer diagnostics and therapeutics, including expanded customer adoption, advanced AI screening tests, and strategic partnerships with leading research centres.

Helios Energy has confirmed significant contingent resources at its Presidio Project in West Texas, supported by new technical partnerships and a strengthened leadership team. The company raised $4.3 million to advance its development plans amid a shifting US energy landscape.

Gold Hydrogen Limited is gearing up for a pivotal 2025 drilling campaign at its Ramsay Project, aiming to further appraise significant natural hydrogen and helium accumulations confirmed in prior exploration. The company also bolsters its technical team and launches a new InvestorHub to deepen stakeholder engagement.

Fin Resources Limited reported subdued exploration activity in Q1 2025 amid weak lithium prices but secured $445,000 via convertible notes and outlined plans for McKenzie Springs exploration.

Inca Minerals has secured over 94% ownership of Stunalara Metals, gaining access to the promising Hurricane Project in North Queensland. With an oversubscribed $1.1 million capital raise, maiden drilling is set to begin in Q2 2025, targeting high-grade gold and antimony mineralisation.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

AnteoTech Ltd reports progress in advanced battery and life sciences technologies alongside a strategic review and leadership changes amid challenging EV market conditions.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Anteris Technologies Global Corp. has filed an amended 10-K to disclose comprehensive governance, executive pay, and related party transactions for fiscal 2024, completing its annual SEC reporting obligations.